Core Viewpoint - The article discusses the imminent adjustment period for the Hong Kong Stock Connect, highlighting the potential inclusion of 31 new stocks, including Jinfang Pharmaceutical, which is expected to meet the entry criteria due to its stable market performance [1][2]. Group 1: Company Performance - Jinfang Pharmaceutical's average market capitalization during the review period is reported at HKD 10.296 billion, exceeding the threshold of HKD 9.242 billion by over HKD 1 billion, indicating a strong likelihood of inclusion in the upcoming adjustment [2]. - The stock experienced significant volatility post-IPO, with a peak increase of 115.79% from the issue price, followed by a decline of 29.31% over a month, reflecting market fluctuations and investor sentiment [3][10]. - After reaching a market cap below HKD 10 billion on October 22, the stock quickly stabilized, avoiding further price bubble risks, aided by its IPO structure which limited short-term selling pressure from retail investors [11]. Group 2: Market Context - The Hong Kong innovative drug sector has seen a substantial rally, with the Hang Seng Healthcare Index rising from a low of 2152.38 points to a high of 4726.41 points, marking a maximum increase of 119.59% over eight months [10]. - Jinfang Pharmaceutical's IPO was highly successful, with a subscription rate of 2662.79 times for the public offering, reflecting strong institutional interest in the KRAS inhibitor sector [10]. - The stock's performance is also influenced by broader market trends, as the Hang Seng Healthcare Index experienced an 11.05% correction in October, impacting investor behavior and contributing to Jinfang's price volatility [10]. Group 3: Technical Analysis - Following a significant drop on October 22, Jinfang Pharmaceutical's stock price rebounded sharply, indicating strong buying interest and a potential shift in market sentiment [4][6]. - The stock has entered a phase of stable horizontal consolidation, with a high concentration of shares held by investors, which reduces the likelihood of significant price fluctuations in the near term [6]. - The average cost of shares held by investors remains around HKD 37, which is significantly above the current market price, further discouraging selling and stabilizing the stock [6].

Core Insights - The research conducted by Fudan University reveals a novel role of Acetyl-CoA as a "metabolic messenger" that directly regulates mitochondrial autophagy, providing a new therapeutic target for overcoming resistance to KRAS inhibitors in pancreatic cancer [1][7]. Group 1: Research Findings - The study highlights that during nutrient scarcity, Acetyl-CoA bypasses the well-known AMPK and mTOR pathways, directly signaling to mitochondria through the protein NLRX1 [1][2]. - The research team utilized CRISPR/Cas9 technology to identify NLRX1 as a key protein involved in this newly discovered signaling pathway [3][4]. - The interaction between Acetyl-CoA and NLRX1 was confirmed through a "molecular fishing" experiment, demonstrating a direct binding relationship [4][5]. Group 2: Implications for Cancer Treatment - The findings indicate that in nutrient-rich conditions, high levels of Acetyl-CoA inhibit mitochondrial autophagy by locking NLRX1 in a dormant state, while nutrient deprivation releases this inhibition, promoting autophagy [6][7]. - The study also uncovers a mechanism by which cancer cells develop resistance to KRAS inhibitors by activating mitochondrial autophagy in response to decreased Acetyl-CoA levels, suggesting a potential new treatment strategy [7][8]. - Targeting the Acetyl-CoA-NLRX1 axis could enhance the effectiveness of KRAS inhibitors, offering new hope for cancer patients facing treatment resistance [7][8].

Core Insights - The research published by Fudan University reveals a novel signaling function of Acetyl-Coenzyme A (AcCoA) in regulating mitophagy through the receptor NLRX1, independent of classical pathways like AMPK and mTOR [3][14][16] - This discovery provides new potential targets and strategies for overcoming resistance to KRAS inhibitors in cancer treatment [3][14][16] Group 1: Mechanism of AcCoA in Mitophagy - AcCoA levels decrease during nutrient deprivation, such as short-term fasting, leading to the activation of mitophagy [5][6] - NLRX1 is identified as a key mediator that directly binds to AcCoA, regulating its signaling role in mitophagy [8][11] Group 2: Experimental Validation - In animal models, fasting resulted in a significant decrease in AcCoA levels in tissues, correlating with increased mitophagy [11] - Supplementing with acetate or knocking out NLRX1 gene can block the fasting-induced mitophagy, indicating the critical role of AcCoA and NLRX1 in this process [11][12] Group 3: Implications for Cancer Treatment - The study indicates that KRAS inhibitors downregulate ACLY expression, reducing AcCoA levels and triggering NLRX1-dependent mitophagy, which may contribute to cancer cell resistance [14] - Short-term fasting may have dual effects in cancer treatment, potentially enhancing immune response while also promoting resistance through mitophagy [14][16] Group 4: Future Directions - Targeting the AcCoA-NLRX1 signaling axis may enhance cancer treatment efficacy and could have implications in various metabolic and neurodegenerative diseases [16]